• More TAVR News; Cystatin-C for STEMI Prognosis; Transpedal Access

    Interventional cardiology news to note

    Medicare proposed expanding payment for transcatheter aortic valve replacement (TAVR). MedPage Today has more about the requirements here.

    Direct TAVR with a CoreValve device skipping the usual step of balloon pre-dilatation was found to be just as safe as when taking this extra step, the DIRECT randomized trial showed. However, it led to more post-dilatation. (JACC: Cardiovascular Interventions)

    Endospan's Nexus stent graft system won regulatory clearance in Europe for endovascular repair of the aortic arch from inside the aorta, Vascular News reported.

    Periprocedural MI was more common after left main revascularization with coronary artery bypass grafting surgery than with percutaneous coronary intervention (PCI), according to a secondary analysis of the EXCEL trial in the European Heart Journal.

    For ST-segment elevation MI patients getting PCI more than 7 days after symptom onset, high cystatin C levels at admission predicted long-term mortality. (Clinical Cardiology)

    Operators reported lower success with transpedal access in infrainguinal peripheral artery disease interventions (94% vs 100%, P=0.0002) but also less use of contrast, less radiation, and shorter fluoroscopy time. (Catheterization and Cardiovascular Interventions)

    Repeat intervention for children stented for an aortic coarctation was mostly successful years later when they grew bigger and needed another stent. Only 9% required a third procedure down the line, researchers reported in EuroIntervention.

    Source:

    Read the original article on Medpage Today: More TAVR News; Cystatin-C for STEMI Prognosis; Transpedal Access

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details